Aims It is uncertain whether the benefit from apixaban varies by type and duration of atrial
fibrillation (AF). Methods and results A total of 18 201 patients with AF [2786 (15.3%) with …

Oral anticoagulant therapy for stroke prevention in atrial fibrillation patients has been
remarkably changed by the introduction of non-vitamin k oral anticoagulants (NOAC) …

Background: History of bleeding is important in decisions for anticoagulation. We analyzed
outcomes in relation to history of bleeding and randomized treatments in patients with atrial …

In the ARISTOTLE trial of apixaban versus warfarin for stroke prevention in patients with
atrial fibrillation, those with two or more dose-reduction criteria (aged≥ 80 years, weight≤ …

Recent studies have shown that implantable cardiac monitors improve the detection of
subclinical atrial fibrillation (AF), but the clinical benefit of anticoagulation is not clear. This …

For more than 50 years, warfarin has been the primary medication used to reduce the risk of
thromboembolic events in patients with atrial fibrillation. Despite its clinical efficacy, warfarin …

The ARISTOTLE trial showed a risk reduction of stroke/systemic embolism (SE) and major
bleeding in non-valvular atrial fibrillation (NVAF) patients treated with apixaban compared to …

We performed a meta-analysis of data on the effectiveness and safety of apixaban
compared with other oral anticoagulants (warfarin or rivaroxaban or dabigatran or …

Aims Warfarin, a vitamin K antagonist (VKA), has been the standard of care for stroke
prevention in patients with atrial fibrillation (AF). Aspirin is recommended for low-risk patients …

Background Warfarin and aspirin are used to prevent stroke in patients with atrial fibrillation
(AF). There are inherent challenges with both treatments, including variable and inconsistent …